Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 12, 2003. The report details a specific corporate action regarding share re-purchases executed in accordance with shareholder authority granted at the Annual General Meeting on May 20, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 950,000 ordinary shares
- Price per Share: 1,040.9086 pence
- Transaction Purpose: Purchase for cancellation
Material Changes
The filing reports a reduction in the company's outstanding share count due to the cancellation of 950,000 shares. No other material changes to operations or financial position are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. The document is strictly a notification of the share re-purchase activity.
Investor Verification Points
- Verify the total number of shares authorized for re-purchase under the May 20, 2002 shareholder resolution to determine remaining capacity.
- Confirm the total cash outflow for this specific transaction (950,000 shares multiplied by 1,040.9086p).
- Check subsequent filings for the impact of this share cancellation on earnings per share (EPS) and total equity.